Slide 1: Q1 FY2026 Financial Results and Business Update
Q1 FY2026 (Fiscal Year Ending March 31, 2027) Financial Results and Business Update Eisai Co., Ltd. August 3, 2026
Slide 2: Today's Speakers
Today’s Speakers Keisuke Naito COO, Chief Growth Officer Takuya Oyama CFO, Chief IR Officer 1
Slide 3: Q1 FY2026 Financial Highlights
Q1 FY2026 Financial Highlights Revenue ◼ 234.3 billion yen +15.6% YoY ◼ Achieved double-digit revenue growth, driven by the strong performance of the Pharmaceutical business (organic business) Operating profit ◼ 24.7 billion yen +19.2% YoY ◼ Double-digit operating profit growth, due to strong growth
Slide 4: Consolidated Statement of Income (IFRS)
Q1 FY2026 Consolidated Statement of Income (IFRS) ◼ Revenue was 234.3 billion yen, achieving 16% YoY growth ◼ Driven by strong growth in the Pharmaceutical business, operating profit increased by 19% YoY, and core operating profit increased by 14% YoY ◼ Showing steady progress toward FY2026 forecast
Slide 5: Analysis of Revenue Increase/Decrease
Analysis of Revenue Increase/Decrease ◼ Revenue increased by 31.7 billion yen, driven by growth of the 3L* products ◼ Pharmaceutical business revenue increased by 16% YoY to 230.9 billion yen Revenue +31.7 billion yen (+15.6%) 2,350 +7.7 -0.8 234.3 Revenue from 2,300 +24.8 Other Other business busin
Slide 6: Analysis of Operating Profit Increase/Decrease
Analysis of Operating Profit Increase/Decrease ◼ Robust growth of the 3L* products led to substantial growth in operating profit and core operating profit 550 Operating profit +4.0 billion yen (+19.2%) 450 +23.2 -4.9 -14.7 R&D expenses 350 24.7 20.7 • Continued proactive Core operating profit Core i
Slide 7: Business and Pipeline Updates
Business and Pipeline Updates ◼ 3L* products business updates ◼ LEQEMBI – Initiatives toward maximizing LEQEMBI value • Approval of LEQEMBI IQLIK for initiation treatment in the U.S. • Establishing a treatment platform leveraging the dosing convenience of LEQEMBI IQLIK • Long-term treatment value of
Slide 8: LENVIMA: Business Updates
LENVIMA: Business Updates Anticancer agent: Contributed to the treatment of approx. 620,000 patients in 83 countries and In-house developed oral multi-kinase inhibitor with 7 indications across 5 cancer types. territories over the 11 years Expanded through monotherapy and combination therapies with
Slide 9: DAYVIGO: Business Updates
DAYVIGO: Business Updates Insomnia treatment: Approved for the treatment of An orexin receptor antagonist developed from an in-house drug discovery platform insomnia in 29 countries and territories, targeting the orexin pathway, which is involved in the regulation of sleep and wakefulness. including
Slide 10: LEQEMBI: Business Updates
LEQEMBI: Business Updates An anti-Aβ antibody which reduces the rate of disease progression and slows the decline Approved in 53 countries and territories in cognitive function and activities of daily living in adults with AD through the clearance of including Japan, U.S., China, EU and neurotoxic A
Slide 11: Maximizing LEQEMBI Value: Approval of LEQEMBI IQLIK
Maximizing LEQEMBI Value: Approval of LEQEMBI IQLIK*1 for initiation treatment in the U.S. ◼ LEQEMBI is an anti-Aβ antibody that slows progression of AD pathology and slows the decline in cognitive function and activities of daily living. It is suitable for long-term treatment. ◼ LEQEMBI is the only
Slide 12: Maximizing LEQEMBI Value: Establishing a treatment foundation
Maximizing LEQEMBI Value: Establishing a treatment foundation for LEQEMBI IQLIK*1 in the U.S. ◼ The approval of LEQEMBI IQLIK as an initiation treatment is expected to support easier initiation and continuation of treatment by expanding patient optionality and strengthening the treatment infrastruct
Slide 13: Maximizing LEQEMBI Value: Long-term treatment value supported by RWE
Maximizing LEQEMBI Value: AAIC2026 Long-term treatment value supported by RWE*1 ◼ LEADER study data*2 from 432 patients with Early AD across 13 clinical practices in the U.S. were presented at AAIC2026.*3,*4 Consistency in long-term and maintenance treatment benefit, and safety profile in LEQEMBI tr
Slide 14: Maximizing LEQEMBI Value: Evolution of diagnostic pathway
Maximizing LEQEMBI Value: Evolution of diagnostic pathway through the implementation of BBM*1 ◼ Aiming to expand LEQEMBI prescribing opportunities through standardizing Aβ diagnosis*2 and improving patient access. Wider adoption of BBM for triage and confirmatory diagnosis, and expansion of treatmen
Slide 15: Next-Generation Drug Discovery Based On AD Continuum (Tau)
Next-Generation Drug Discovery Based On AAIC2026 AD Continuum (ATN*1) Tau ◼ MTBR-tau243 is included as a tau pathology biomarker (T2) in the Alzheimer's Association's biological diagnostic criteria.*2 ◼ Measurement of plasma eMTBR*3-tau243 enabled assessment of the pharmacodynamic effects of etalane
Slide 16: Next-Generation Drug Discovery Based On AD Continuum (ATN)
Next-Generation Drug Discovery Based On AD Continuum (ATN*1) ◼ Striving to “Make AD a Curable Disease” Amyloid Tau Neurodegeneration A T N Fibril Lecanemab Slows Tau Pathology E2511*2 Protofibril Plaque Lecanemab Lecanemab Slows Slows Tau Tau Pathology Pathology Restoring neuronal function through T
Slide 17: Orexin Pathway Platform: From sleep/wake toward brain function regulation
Orexin Pathway Platform: From sleep/wake toward brain function network regulation Lemborexant: DORA*1 Ledasorexton*3: Orexin 2 receptor agonist ◼ Proof of Concept (POC) in Study 202: Insomnia Chronic insomnia*2 NT1 and NT2 are evaluated in the same study Approved in Japan, U.S., Under review Topline
Slide 18: Pipeline
Pipeline Neurodegeneration Target Indication Development Stage Key Events Strategic positioning in the three-year plan*2 ATN*1 Continuum Approved for initiation treatment: 53 countries and territories AD Continuum, Aβ Early AD (IV initiation/ maintenance) Global submission/approval Approved for main
Slide 19: Key Takeaways
Key Takeaways Highlights of Management Foundation • Strong growth of the 3L products drove year-on-year increases in both revenue and operating profit, supporting steady progress toward the FY2026 forecast Highlights of Business Growth • LENVIMA: Continued sustainable growth, primarily driven by the
Slide 20: Reference Data
Reference Data
Slide 21: Consolidated Statement of Income
Consolidated Statement of Income FY2025 FY2026 (billions of yen, %) April-June Results Ratio(%) April-June Results Ratio(%) YOY(%) Diff. Full year forecast Ratio(%) Prog.(%) Revenue 202.7 100.0 234.3 100.0 15.6 31.7 883.5 100.0 26.5 Pharmaceutical Business 198.4 97.9 230.9 98.5 16.4 32.5 870.0 98.5
Slide 22: Segment Revenue
Segment Revenue FY2025 FY2026 April-June April-June Full year Share(%) Share(%) YOY(%) Prog.(%) (billions of yen, %) Results Results forecast Pharmaceutical Business Total 198.4 97.9 230.9 98.5 16.4 870.0 26.5 Japan pharmaceutical business 56.0 27.7 57.9 24.7 3.4 233.5 24.8 Americas pharmaceutical b
Slide 23: Segment Profit
Segment Profit FY2025 FY2026 April-June April-June Share(%) Share(%) % of revenue YOY(%) (billions of yen, %) Results Results Pharmaceutical Business Total 95.3 97.7 116.1 98.9 50.3 21.7 Japan pharmaceutical business 19.4 19.9 21.0 17.9 36.3 8.1 Americas pharmaceutical business 41.5 42.6 51.9 44.3 6
Slide 24: Revenue from Major Products
Revenue from Major Products FY2025 FY2026 April-June April-June Share (%) Share (%) YOY (%) Full year forecast Prog. (%) (billions of yen, %, ＜＞CER YOY) Results Results Major Products (3L) 120.7 － 145.5 － 20.5 562.0 25.9 <9.9> Lenvima/Kisplyx 83.9 100.0 97.3 100.0 15.9 345.0 28.2 <4.3> Japan 3.6 4.3
Slide 25: Performance of Japan Pharmaceutical Business
Performance of Japan Pharmaceutical Business FY2025 FY2026 April-June April-June Full year Share (%) Share (%) YOY (%) Prog. (%) (billions of yen, %) Results Results forecast Revenue 56.0 100.0 57.9 100.0 3.4 233.5 24.8 Japan pharmaceutical business 50.6 90.4 52.7 91.0 4.1 211.0 25.0 OTC and others
Slide 26: Performance of Americas Pharmaceutical Business
Performance of Americas Pharmaceutical Business FY2025 FY2026 April-June April-June Share (%) Share (%) YOY (%) Full year forecast Prog. (%) (billions of yen, %, ＜＞CER YOY) Results Results Revenue 70.8 100.0 86.6 100.0 22.3 337.0 25.7 <10.9> United States 68.9 97.3 83.8 96.7 21.6 324.0 25.8 <10.3> S
Slide 27: Performance of China Pharmaceutical Business
Performance of China Pharmaceutical Business FY2025 FY2026 April-June April-June Share (%) Share (%) YOY (%) Full year forecast Prog. (%) (billions of yen, %, ＜＞CER YOY) Results Results Revenue 36.5 100.0 42.5 100.0 16.6 147.0 28.9 <-0.3> Segment profit 17.9 49.1 21.2 49.8 18.2 － － <-1.3> China - re
Slide 28: Performance of EMEA Pharmaceutical Business
Performance of EMEA Pharmaceutical Business FY2025 FY2026 April-June April-June Share (%) Share (%) YOY (%) Full year forecast Prog. (%) (billions of yen, %, ＜＞CER YOY) Results Results Revenue 19.0 100.0 23.6 100.0 24.4 73.0 32.4 <8.7> Segment profit 8.2 43.1 12.5 52.7 51.8 － － <39.7> EMEA - revenue
Slide 29: Performance of East Asia Global South Pharmaceutical Business
Performance of East Asia Global South Pharmaceutical Business FY2025 FY2026 April-June April-June Share (%) Share (%) YOY (%) Full year forecast Prog. (%) (billions of yen, %, ＜＞CER YOY) Results Results Revenue 16.1 100.0 20.2 100.0 25.3 79.5 25.4 <16.2> Segment profit 8.2 51.1 9.5 46.9 15.0 － － <4.
Slide 30: Safe Harbor Statement
Safe Harbor Statement ◼ Forecast or target figures in this material are not official earnings guidance but represent midterm strategies, goals, and visions. Official earnings guidance should be referred to in the disclosure of the annual financial report (Consolidated Financial Statement) in accorda